MI-CP204
Laufzeit: 01.01.2012 - 31.12.2012
Kurzfassung
An open-label, phase 1/2 study of MEDI-551, a humanized monoclonal antibody directed against CD19, in adult subjects with relapsed or refractory advanced B-cell malignancies
Laufzeit: 01.01.2012 - 31.12.2012
An open-label, phase 1/2 study of MEDI-551, a humanized monoclonal antibody directed against CD19, in adult subjects with relapsed or refractory advanced B-cell malignancies
